PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial

Andrea Necchi(Vita-Salute San Raffaele University), Filippo de Braud(University of Milan), Maria Grazia Daidone(Fondazione IRCCS Istituto Nazionale dei Tumori), Marzia Pennati(Fondazione IRCCS Istituto Nazionale dei Tumori), Massimo Maffezzini(Fondazione IRCCS Istituto Nazionale dei Tumori), E. Togliardi(Fondazione IRCCS Istituto Nazionale dei Tumori), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Nicola Nicolai(Fondazione IRCCS Istituto Nazionale dei Tumori), Nadia Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Alfonso Marchianò(Fondazione IRCCS Istituto Nazionale dei Tumori), Roberto Salvioni(Neurology, Inc), Patrizia Giannatempo(Fondazione IRCCS Istituto Nazionale dei Tumori), Luigi Mariani(Fondazione IRCCS Istituto Nazionale dei Tumori), A. M. Gianni(Azienda Ospedaliero Universitaria San Giovanni Battista), Flavio Crippa(National Cancer Institute), Elena Farè(Fondazione IRCCS Istituto Nazionale dei Tumori)
Investigational New Drugs
February 25, 2014
10.1007/s10637-014-0074-9
Cited by 54

Related Papers

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k